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ADAM10 Is Upregulated in Melanoma Metastasis
Compared with Primary Melanoma
Sophia B. Lee1,8, Anja Schramme1,8,9, Kai Doberstein1,8, Reinhard Dummer2,
Mohamed S. Abdel-Bakky1, Sascha Keller3, Peter Altevogt3, Shin T. Oh4,5, Jo¨rg Reichrath4,
Daniel Oxmann6, Josef Pfeilschifter1, Daniela Mihic-Probst7,8 and Paul Gutwein1,8
ADAM10 (a disintegrin and metalloproteinase 10) is involved in the ectodomain shedding of various substrates,
including adhesion molecules such as L1 cell adhesion molecule (L1-CAM) and CD44, which are known to have
important roles in the development of malignant melanoma. In our study, we characterized the expression of
ADAM10 in melanoma cells in vitro and in vivo. Immunohistochemical analysis on tissue microarrays indicated
that ADAM10 expression was significantly elevated in melanoma metastasis compared with primary melanomas.
In vitro downregulation of ADAM10 with specific small interfering RNA (siRNA) resulted in a suppression of the
anchorage-independent cell growth and reduced the migration of melanoma cells. In addition, overexpression
of ADAM10 induced the migration of melanoma cells. In cell lines from melanoma patients with metastasis,
ADAM10 was significantly overexpressed, and ADAM10 expression correlated with increased cell proliferation.
Furthermore, we present evidence that ADAM10 is involved in the release of L1-CAM from melanoma cells. It is
important that knockdown of cellular L1-CAM reduced the migration of melanoma cells and abrogated the
chemoresistance against cisplatin. In contrast, soluble L1-CAM had no effect on melanoma cell migration or cell
survival. Taken together, our data demonstrate that ADAM10 and L1-CAM have important roles during
melanoma progression and both molecules represent attractive targets for therapeutical intervention of
melanomas.
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INTRODUCTION
Malignant melanoma represents a substantial clinical chal-
lenge. It is one of the fastest-rising malignancies in the past
several decades (Ries et al., 2000) and it is notorious for the
propensity for metastization and for the poor response to
current therapeutic regimens. Understanding the molecular
aberrations involved in the development and progression of
malignant melanoma will be therefore essential for better
diagnosis and rational design of effective therapeutics.
Different members of the ADAM (a disintegrin and
metalloproteinases) family are involved in signaling events
that are dysregulated in cancers and/or during tumor
progression (Mochizuki and Okada, 2007). In many cancers,
ADAMs are upregulated (Mochizuki and Okada, 2007) and
several recent studies have highlighted the potential of
targeting ADAM family members as a new approach for
antitumor therapy (Borrell-Pages et al., 2003; Zhou et al.,
2006; Kenny and Bissell, 2007). The disintegrin–metallopro-
teinase ADAM10 has been found to be upregulated in many
cancers including ovary, colon and prostate cancers (Arribas
et al., 2006; Santiago-Josefat et al., 2007). It has been shown
that overexpression of ADAM10 promoted the growth of oral
squamous cell carcinoma and gastric carcinoma, in contrast
downregulation of its expression with antisense oligonucleo-
tides or treatment with anti-ADAM10 antibodies (Abs)
reduced proliferation of carcinoma cells (Carl-McGrath
et al., 2005; Ko et al., 2007). It is important that, ADAM10
can process several molecules involved in cancer develop-
ment and tumor progression. For example, adhesion
molecules such as L1 cell adhesion molecule (L1-CAM),
CD44, E-cadherin, and N-cadherin have been identified as
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substrates for the ADAM10 sheddase and are associated with
tumor cell migration and invasion (Gutwein et al., 2003;
Nagano et al., 2004; Reiss et al., 2005; Stoeck et al., 2006).
Furthermore, ADAM10 can also process receptors such as IL-
6R, CD30, HER2 and components of the Notch signaling
pathway, which has a significant role in diverse processes
during tumor development and progression (Hartmann et al.,
2002; LaVoie and Selkoe, 2003; Matthews et al., 2003; Liu
et al., 2006; Eichenauer et al., 2007). It can be noted that, for
several prominent substrates of ADAM10 including L1-CAM,
E-cadherin, and CD44, a role in the initiation and/or
progression of melanomas has been described (Kobayashi
et al., 1991; Hirohashi, 1998; Guilford, 1999). However,
only few data exist regarding the role of ADAM10 in the
development of melanoma. Therefore, we characterized the
expression of ADAM10 in tissue microarrays (TMAs) of
melanoma patients and determined its functional role in
melanoma cell lines.
We found a heterogeneous expression of ADAM10 in
melanoma. ADAM10 expression was increased in vitro and
in vivo in melanoma metastasis compared with primary
melanoma. Using ADAM10-specific small interfering RNA
(siRNA) and an ADAM10 expression plasmid, we could show
that ADAM10 expression correlated with an increased
melanoma cell proliferation and cell migration. In addition,
ADAM10 was involved in the release of L1-CAM from
melanoma cells. The knockdown of L1-CAM reduced the
migration of melanoma cells and importantly abrogated the
chemoresistance against cisplatin. Our results suggest that
ADAM10 and L1-CAM have important roles in the progres-
sion of melanoma and may therefore serve as attractive target
proteins for therapeutical intervention of melanomas.
RESULTS
ADAM10 expression in normal epidermis and acquired benign
melanocytic nevi
Cytoplasmic staining for ADAM10 was detected in the basal
cell layers of the epidermis. In the dermal compartment,
ADAM10 expression was found in cells of hair follicles,
sebaceous glands, and eccrine sweat glands. Cytoplasmic
ADAM10 expression was moderate or strong in melanocytic
nevi. ADAM10 expression was more prominent in the
junctional and superficial part of compound nevi (Figure 1).
ADAM10 expression and melanoma progression
We investigated the ADAM10 expression in TMAs of primary
melanomas and melanoma metastasis. The tumor samples
were not matched. We found absent, weak, moderate, or
strong ADAM10 expression in melanomas (Figure 2). The
tumor cells showed a cytoplasmic positivity with accentua-
tion to the cell membrane (Figure 2a). Over 80% of cells in
one tumor showed the same staining intensity. Basal
keratinocytes with strong ADAM10 expression were used as
a positive internal control (Figure 2b). Papillary renal
carcinoma was used as a positive external control (data not
shown). The absence of ADAM10 expression was found in 16
of 46 (35%) primary melanomas. Of 46 primary melanomas,
16 had weak, 10 (22%) moderate, and 4 (8%) had strong
ADAM10 expression. Melanoma metastasis had a significant
higher ADAM10 expression compared with primary melano-
mas (P¼ 0.04). Of 127 metastasis, 22 (17%) showed strong,
41 (32%) moderate, and 31 (25%) showed weak expression,
and 33 were negative. Interestingly, some melanomas
showed nuclear positivity in few tumor cells (o10%, Figure
2d). Nuclear positivity for ADAM10 was observed more often
in metastasis (44%) compared with primary melanoma
(35%). However, this difference did not reach statistical
significance. We could neither in TMAs nor in whole
embedded tumors observe a difference in ADAM10 expres-
sion between the junctional and infiltrative part of primary
melanoma or between the center and the periphery of
melanoma metastases.
We found no correlation between ADAM10 expression
and proliferation in primary melanoma or metastases.
Breslow tumor thickness was not associated with ADAM10
expression.
ADAM10 and L1-CAM expression in melanoma tissue
ADAM10 can cleave L1-CAM, and L1-CAM is known to
promote melanoma progression (Gutwein et al., 2003; Meier
et al., 2006). To determine the expression frequencies of L1-
CAM, the percentage of positive cells were graded as
followed: 1¼up to 10%, 2¼11–50%, 3¼ 51–90%,
4Z90% positive cells. Whenever L1-CAM protein was
detected, strong L1-CAM expression was observed. Of 173,
65 (38%) melanomas had a score of 1, 35 (21%) a score of 2,
29 (17%) a score of 3, and 44 (25%) a score of 4. There was
no difference in the L1-CAM expression between primary
melanoma and metastasis. Neither was there a significant
correlation between ADAM10 and L1-CAM expression (data
not shown). Double immunofluorescence analysis of mela-
nomas with strong ADAM10 expression in melanoma cells
showed a heterogeneous expression pattern for L1-CAM.
Some melanoma cells showed colocalization of both proteins
(Figure 2g merged picture, yellow arrows), whereas some
ADAM10 overexpressing melanoma cells did not express
L1-CAM (Figure 2g merged picture, white stars). These
observations were also made using conventional immuno-
histochemical analysis with serial sections (data not shown).
200 μM
Figure 1. ADAM10 expression in acquired benign melanocytic nevi.
Nevus of the compound type with moderate ADAM10 expression in the
junctional superficial part (arrow) and weak expression in the deep dermal
part. Strong ADAM10 expression in basal keratinocytes. Bar¼200 mM.
ADAM, a disintegrin and metalloproteinase.
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ADAM10 is expressed in keratinocytes and melanoma cell lines
To investigate whether ADAM10 is expressed in keratino-
cytes and melanoma cell lines in vitro, we performed FACS
analysis. The amount of cell surface-expressed ADAM10 was
very similar in HaCaT, Sk Mel 5, and MeWo cells (Figure 3a
left panel). In addition, we analyzed the expression of
L1-CAM by FACS. All three cell lines expressed L1-CAM to
similar levels at the cell surface (Figure 3a right panel). By
immunofluorescence microscopy, we confirmed the protein
expression of ADAM10 and L1-CAM in all three cell lines
(Figure 3b). It is interesting that, ADAM10 was mainly
localized in the membrane and the cytoplasm, but a small
proportion of ADAM10 was also detectable in nuclei of
HaCaT and melanoma cells. The specificity of our L1-CAM
and ADAM10 immunofluorescence staining was controlled
by using isotype-specific control Abs (Figure 3b right panel,
control IgG). To confirm the nuclear ADAM10 expression in
melanoma cells, nuclei of the cells were isolated biochemi-
cally as described under Materials and Methods section and
ADAM10 expression was investigated by western blot
analysis. As documented in Figure 3c, the ADAM10
expression was only found in the cell lysates but not in the
nuclear fraction of melanoma cells. Interestingly, western
blot analysis further indicated that HaCaT keratinocytes and
Sk Mel 5 cells expressed mainly the immature form of
ADAM10, whereas in MeWo cells the mature ADAM10 was
the predominant form (Figure 3d). In addition, we present
evidence that MeWo cells released almost 12-fold higher
levels of soluble L1-CAM than HaCaT cells (Figure 3e).
Furthermore, by using ADAM10-specific siRNA, we could
show that ADAM10 is involved in the release of L1-CAM
from MeWo cells (Figure 3f). L1-CAM has an important role
in tumor cell migration and tumor cell survival (Gavert et al.,
2008). We found that the knockdown of cellular L1-CAM by
specific siRNA (Figure 3g) reduced the migration of MeWo
cells (Figure 3h) and importantly abrogated the chemoresis-
tance of melanoma cells against cisplatin (Figure 3i). In
contrast, soluble L1-Fc had no effect on cell migration and
cell survival (data not shown), but increased the adhesion of
MeWo cells (Figure 3j).
ADAM10 and L1-CAM expression in a melanoma cell line array
We investigated the ADAM10 and L1-CAM expression in a
melanoma cell array derived from 50 melanoma patients.
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Figure 2. ADAM10 expression in tissue biopsies of melanoma patients.
(a) Strong cytoplasmic ADAM10 expression with membranous accentuation
in primary malignant melanoma (bar¼ 50 mM). (b) Moderate cytoplasmic
ADAM10 expression in dermal nevus with strong positive internal control of
basal keratinocytes (bar¼ 100mM). (c and d) Immunohistochemical analysis of
ADAM10 expression in tissue sections of melanoma metastasis. (c) Weak
cytoplasmic ADAM10 expression (bar¼20 mM). (d) Absence of cytoplasmic
ADAM10 expression and nuclear positivity of a tumor cell is indicated by an
arrow (bar¼ 20 mM). (e and f) Primary melanoma at the dermoepidermal
junction with epidermotropism (arrows). (e) Absence of ADAM10 expression
with strong positive internal control of basal keratinocytes. (f) L1-CAM
expression is detectable in over 50% of melanoma cells (bars¼ 50 mM).
(g) Double immunofluorescence analysis on a tissue section of a melanoma
patient. L1-CAM expression was visualized by monoclonal L1-CAM antibody
(Ab) followed by Alexa Flour 488–coupled secondary Ab (green). ADAM10
expression was detected by polyclonal ADAM10 Ab and Cy3-coupled
secondary Ab. Nuclei of melanoma cells were stained with DAPI. Arrows in
the merged picture indicate colocalization of L1-CAM and ADAM10 in
melanoma cells. Bar¼ 50mM. ADAM, a disintegrin and metalloproteinase;
DAPI, 4,06-diamidino-2-phenylindole; L1-CAM, L1 cell adhesion molecule.
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Of 50 cell lines, only 3 (6%) were negative for ADAM10,
whereas 17 (34%) cell lines showed weak, 23 (46%)
moderate, and 7 (14%) showed strong ADAM10 expression
(data not shown). Cell lines derived from metastasis
compared with those from primary tumors had significantly
more ADAM10 expression (Figure 4).
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ADAM10 expression in cell lines was significantly
associated with proliferation (P¼ 0.001) (Table 1). In addi-
tion, there was a significant correlation between ADAM10
and L1-CAM expression (P¼ 0.001) (Table 1). However,
seven cases had a moderate or strong ADAM10 expression
and L1-CAM expression was absent (data not shown).
Knockdown of ADAM10 by siRNA inhibits proliferation and
migration of melanoma cells
Besides other phenotypic traits, anchorage-independent cell
growth is one major characteristic of malignant melanoma
cells. Therefore, we evaluated the influence of ADAM10
knockdown on anchorage-independent and anchorage-de-
pendent cell growth (Figure 5). As shown in Figure 5a, in
MeWo cells the transfection of ADAM10-specific siRNAs
resulted in an almost complete loss of ADAM10 protein
expression for 48 hours after the transfection, which persisted
for at least 72 hours (data not shown). Interestingly, the
knockdown of ADAM10 had no influence on the prolifera-
tion of adherent MeWo cells (Figure 5b). In contrast, the
anchorage-independent cell growth of MeWo cells was
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Figure 4. ADAM10 expression in melanoma cell array. Analysis of ADAM10
expression in melanoma cell lines derived from 50 melanoma patients:
ADAM10 expression in cell lines of primary melanomas (1) as compared to
melanoma cell lines of melanoma metastasis (2). Absent (0), weak (1),
moderate (2), and strong (3) ADAM10 expression was observed. 1 Three cell
lines showed weak ADAM10 expression, and * indicates one cell line had no
ADAM10 expression. ADAM, a disintegrin and metalloproteinase.
Table 1. Melanoma cell lines derived from 50
melanoma patients: correlation between ADAM10
expression and proliferation or L1-CAM expression
Percentage of
proliferating tumor cells
L1-CAM expression
in tumor cells
ADAM10 expression
(number of cases) p5% 45% p50% 450%
Absent 3 0 3 0
Weak 10 7 16 1
Moderate 4 19 11 12
Strong 0 7 2 5
P-value 0.0001 0.001
ADAM, a disintegrin and metalloproteinase.
Absent (0), weak (1), moderate (2), strong (3) ADAM10 expression.
Figure 3. Expression of ADAM10 and L1-CAM in keratinocytes and melanoma cell lines. (a) Cell surface expression of ADAM10 (left panel) and L1-CAM
(right panel) in human keratinocyte cell line HaCaT and the melanoma cell lines MeWo and Sk Mel 5 cells. Flow cytometry histograms represent number of cells
(cell counts, y axis) and the fluorescence intensity (x axis) of ADAM10, L1-CAM, and the isotype-matched control IgG antibody (Ab) (filled peak).
(b) Immunofluorescence staining of HaCaT, MeWo, and Sk Mel 5 cells with ADAM10 (green)- or L1-CAM (red)-specific Abs. The cells were stained with DAPI
to visualize nuclei (blue), and with Alexa Flour 488–coupled secondary Ab to detect the distribution of ADAM10 protein or a Cy3-coupled Ab to visualize
L1-CAM expression. The specific ADAM10 and L1-CAM expression was controlled by using isotype-specific control (control IgG) Abs (right panel)
(bars¼ 50 mM). (c) Total cell lysates and nuclear extracts of MeWo cells were investigated by western blot analysis with an ADAM10-specific Ab. The purity of
the isolated nuclei was controlled by compartment-specific markers such as BiP/GRP78 (endoplasmatic reticulum) and HDAC-1 (nucleus). (d) Western blot
analysis of ADAM10 in HaCaT, MeWo, and Sk Mel 5 cells. b-Actin levels were determined as a loading control. (e) HaCaT and MeWo cells were serum-starved
for 24 hours, supernatants were centrifuged, and soluble proteins were trichloroacetic acid (TCA) precipitated. Equal protein amounts (triplicats of each cell line)
were loaded on a SDS gel, and the constitutive release of L1-CAM was investigated by western blot analysis using L1-CAM-specific Ab. (f) MeWo cells
were transfected with scrambled small interfering RNA (siRNA), ADAM10-, or L1-CAM-specific siRNA. At 24 hours after transfection, 25 ngml1 phorbol ester
(PMA) was added to the cells, supernatants were trichloroacetic acid (TCA) precipitated, and total cell lysates were prepared. Western blot analysis was carried
out to determine L1-CAM and ADAM10 expression. b-Actin was used as a loading control. (g) Cell lysates of MeWo cells were analyzed by L1-CAM-specific
western blot 48 hours after siRNA transfection. Mock (transfection reagent alone), scrambled siRNA (sc-siRNA), and L1-CAM-specific siRNA (L1-siRNA). b-Actin
levels were determined as a loading control. (h) Migration of MeWo cells transfected with siRNAs specific for L1-CAM (L1-siRNA) or scrambled-siRNA
(sc-siRNA). At 48 hours after siRNA transfection, cells were analyzed in a migration assay (membranes were coated with fibronectin) as described in Materials
and Methods. ***Po0.001 considered statistically significant compared with mock-transfected melanoma cells (Mock). ###Po0.001 considered statistically
significant compared with sc-siRNA-transfected melanoma cells. (i) The percentage of apoptotic Sk Mel 5 cells. At 48 hours after siRNA transfection, cells
were left untreated or treated for 24 hours with 40 mM cisplatin (CDDP). Melanoma cells were collected and analyzed with cell-cycle analysis as described in
Materials and Methods. The percentage of cells in sub-G1 phase (apoptotic cells) after the treatment is shown in the graph. ***Po 0.001 considered statistically
significant compared with mock-transfected melanoma cells treated with cisplatin (MockþCDDP). ##Po0.05 considered statistically significant compared
with sc-siRNA-transfected and cisplatin-treated melanoma cells (sc-siRNAþCDDP). (j) Adhesion assay of MeWo cells on fibronectin (10 mgml1)- or soluble
L1-Fc (6.4 and 64mgml1)-coated 24-well plates. ***Po 0.001 considered statistically significant compared with phosphate-buffered saline (PBS)-treated
24-well plates. ADAM, a disintegrin and metalloproteinase; DAPI, 4,06-diamidino-2-phenylindole; L1-CAM, L-1 cell adhesion molecule.
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Figure 5. Knockdown of ADAM10 decreases migration and proliferation of melanoma cells. (a) Western blot analysis of ADAM10 expression at 48 hours
after the transfection of ADAM10-specific small interfering RNA (siRNA) in MeWo cells. The blot was stripped and re-probed with an b-actin-specific antibody
(Ab) as a loading control. (b) Anchorage-dependent and (c) anchorage-independent growth of MeWo cells transfected with ADAM10-specific siRNAs. At
24 hours after the siRNA transfection, cells were seeded into polyHEMA-coated 96-well plates, and at 24, 48, and 72 hours later, growth was measured at
570 nm using an MTT¼3-(4,5-Dimethyl-2-yl)-2,5-diphenyltetrazolium bromide assay. *Po0.05 considered statistically significant compared with scrambled
siRNA-transfected cells (sc-siRNA). (d) Western blot analysis of ADAM10 expression at 48 hours after the transfection of ADAM10-specific siRNA in Sk Mel 5
cells. The blot was stripped and re-probed with an b-actin-specific Ab as a loading control. (e) Anchorage-dependent (f) and anchorage-independent growth of
Sk Mel 5 cells transfected with ADAM10-specific siRNAs. ***Po 0.001 considered statistically significant compared with scrambled siRNA-transfected cells
(sc-siRNA). (g) Migration of MeWo cells transfected with siRNAs specific for ADAM10 (A10-siRNA) or scrambled-siRNA (sc-siRNA). At 24 hours after
siRNA transfection, cells were analyzed in a migration assay (membranes were coated with fibronectin) as described in Materials and Methods. ***Po0.001
considered statistically significant compared with mock-transfected cells (Mock). ##Po0.01 considered statistically significant compared with sc-siRNA-
transfected cells. (h) Migration of MeWo cells after the transfection with ADAM10 or scrambled siRNA. Transmigration membranes were coated with Matrigel;
24 hours after siRNA transfection, cells were counted, and cell migration was performed and analyzed as described under Materials and Methods. ***Po0.001
considered statistically significant compared with mock-transfected cells (Mock). ###Po0.001 considered statistically significant compared with scrambled
siRNA-transfected cells (sc-siRNA). ADAM, A Disintegrin And Metalloproteinase.
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significantly reduced by the transfection of ADAM10-specific
siRNAs in comparison with the controls (Figure 5c). In
addition, we investigated the role of ADAM10 in proliferation
of Sk Mel 5 cells, which only express low levels of mature
ADAM10 (Figure 3d). As shown in Figure 5d, at 48 hours after
siRNA transfection, ADAM10 protein expression was com-
pletely downregulated. Interestingly, in SK Mel 5 cells, the
knockdown of ADAM10 (Figure 5d) significantly inhibited
anchorage-dependent (Figure 5e) as well as anchorage-
independent cell growth (Figure 5f). Furthermore, ADAM10
knockdown reduced the migration of MeWo cells through
fibronectin (Figure 5g)- and Matrigel (Figure 5h)-coated
membranes.
To investigate the role of ADAM10 overexpression in
melanoma, we transfected ADAM10 cDNA in MeWo cells
and carried out migration and cell proliferation assays.
Transfection of ADAM10 plasmid DNA led to a significant
increase in the cellular ADAM10 protein expression as
documented by immunofluorescence (Figure 6a) and western
blot analysis (Figure 6b). ADAM10 overexpression resulted in
a significant increase in MeWo cell migration (Figure 6c).
In addition, we observed an induction of cell proliferation
after ADAM10 overexpression, but this induction did not
reach statistical significance (data not shown).
DISCUSSION
Melanoma is one of the rarer types of skin cancer but causes
the majority of skin cancer-related deaths. It is mainly due to
uncontrolled growth of melanocytes. Despite many years of
intensive laboratory and clinical research, the sole effective
cure is surgical resection of the primary tumor before it
achieves metastatic disease. Therefore, it is of high impor-
tance to understand the mechanisms of melanoma initiation
and progression to develop new therapeutic strategies to
prevent and cure the disease.
In this context, ADAMs are an attractive family of
molecules. A variety of ADAMs including ADAM10 have
been found to be overexpressed in cancer (Mochizuki and
Okada, 2007). Increased expression of ADAM10 has been
described in oral squamous cell carcinoma (Ko et al., 2007).
Interestingly, the transfection of ADAM10 antisense-oligo-
deoxynucleotides resulted in a significant reduction of
cellular growth of oral squamous cancer cells (Ko et al.,
2007). Recently, ADAM10 has been shown to cleave CD44
in melanoma cells (Anderegg et al., 2009). In addition, the
same authors described ADAM10 expression in melanoma
tissue (Anderegg et al., 2009), although only few tissue
sections were analyzed. Therefore, we investigated the
expression of ADAM10 in TMAs, representing 46 primary
melanomas and 127 melanoma metastasis. Importantly, we
found a heterogeneous expression of ADAM10 in melanoma
tissue and melanoma cell lines. In cell lines as well as in
tumor tissue, the protein was significantly upregulated in
metastasis compared with primary tumors, assuming an
important role of ADAM10 in the progression of melanoma.
In addition, ADAM10 expression correlated with increased
cell proliferation. By downregulation of ADAM10 with
ADAM10-specific siRNA, we could significantly inhibit the
anchorage-independent cell growth of melanoma cells
providing further data that underline the importance of
ADAM10 in the progression of malignant melanoma.
ADAM10 can cleave several critical transmembrane
molecules including amyloid precursor protein. It is noted
that, soluble amyloid precursor protein has been related to
the growth of keratinocytes, melanocytes, and melanoma
cells (Hoffmann et al., 2000; Schmitz et al., 2002; Quast
et al., 2003), which suggests that ADAM10 may influence the
growth of melanoma cells by the shedding of amyloid
precursor protein. Besides amyloid precursor protein, other
substrates of ADAM10 have been associated with cancer
development and tumor progression. The loss of E-cadherin
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Figure 6. Overexpression of ADAM10 induces the migration of melanoma
cells. MeWo cells were transfected with pcDNA 3.1 or with ADAM10
pcDNA 3.1 plasmid DNA. ADAM10 overexpression was visualized by
immunofluorescence (a) using monoclonal ADAM10 antibody (Ab) followed
by Alexa Flour 488–coupled secondary Ab (green); nuclei were stained with
DAPI (blue; bars¼ 50mm) or by western blot analysis (b) using ADAM10-
specific polyclonal Abs. The membranes were re-probed with b-actin Abs to
indicate equal protein loading. (c) ADAM10-overexpressing cells were
analyzed in a cell migration assay. At 48 hours after pcDNA 3.1 or ADAM10
pcDNA 3.1 transfection, cells were counted and placed on fibronectin-coated
Transwell membranes. After 24 hours, transmigrated cells were analyzed as
described by Materials and Methods. ***Po0.001 considered statistically
significant compared with pcDNA 3.1–transfected cells. ADAM, a disintegrin
and metalloproteinase; DAPI, 4,06-diamidino-2-phenylindole.
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appears to be one of the critical steps in the progression of
melanoma. E-cadherin is a transmembrane molecule, which
functions as an adhesion molecule. In normal human
epidermis, E-cadherin is localized at the intercellular borders
between keratinocytes and melanocytes (Tang et al., 1994).
Keratinocytes control melanocyte growth and behavior
through a complex system of paracrine growth factors and
cell–cell adhesion molecules, for example, E-cadherin
(reviewed in Haass et al., 2005). The loss of E-cadherin in
melanoma cells could trigger the release of cancer cells from
the primary tumor by subsequent breakdown in the
melanocytes–keratinocytes interaction and invasion of carci-
noma cells (Danen et al., 1996; Hsu et al., 1996).
Interestingly, ectopic E-cadherin expression inhibits the
invasion of melanoma cells into the dermis (Hsu et al.,
1996). This suggests that increased expression of ADAM10
may lead to elevated shedding of E-cadherin and loss of
cell–cell contacts. Lochter et al. (1997) have already
suggested that E-cadherin-mediated cell adhesion might be
abrogated through degradation of the extracellular portion by
proteases such as matrix metalloproteinase 3. Interestingly,
matrix metalloproteinase 3 is strongly expressed in malignant
melanomas (Bodey et al., 2001).
Furthermore, expression of several components of the
Notch pathway, which can be cleaved by ADAM10, was
upregulated in melanomas compared with common melano-
cytic nevi (Massi et al., 2006). Therefore, the activation of
Notch may represent an early event in melanocytic tumor
growth and the upregulation of Notch signaling may sustain
tumor progression.
A potential role of L1-CAM in tumor progression is
suggested by its widespread expression on many different
cancer types including melanoma (Gavert et al., 2008).
Elevated levels of L1-CAM on a metastatic variant of a
melanoma cell line suggested a role for L1-CAM in tumor
progression (Linnemann et al., 1989). Importantly, our data
support the denotation of L1-CAM in the pathogenesis of
melanoma. We discovered that the knockdown of L1-CAM
by specific siRNA reduced the migration of melanoma cells
and abrogated the chemoresistance of melanoma cells
against cisplatin. Our data are in line with a study showing
that L1-CAM Abs can reduce the migration of melanoma cells
(Meier et al., 2006). In addition, the efficacy of anti-L1-CAM
Ab treatment in suppressing tumor growth was already shown
in nude mice, in which it was possible to inhibit the
intraperitoneal proliferation and spread of L1-CAM expres-
sing ovarian cancer cells by intraperitoneal injections of anti-
L1-CAM Abs (Arlt et al., 2006). Further studies indicated that
L1-CAM Abs can also be used to deliver chemical and
radioactive therapies to L1-CAM-expressing cancer cells.
Therefore, our finding that L1-CAM expression confers
chemoresistance in melanoma cells confirms the therapeutic
potential of targeting L1-CAM in the treatment of melanoma.
In addition, we present evidence that ADAM10 is involved in
the release of L1-CAM from melanoma cells. It has been
shown that soluble L1-CAM can induce cell migration
through binding to integrins (Mechtersheimer et al., 2001).
In contrast, we did not find an induction of melanoma cell
migration by soluble L1-CAM, but an increased adhesion of
melanoma cells. Soluble L1-CAM can be deposited in the
extracellular matrix (Montgomery et al., 1996). Therefore,
soluble L1-CAM in the extracellular matrix could have an
important role in the adhesion of melanoma cells by
heterophilic (L1-CAM and integrins) or homophilic interac-
tions (L1-CAM and L1-CAM). In addition, a recent paper has
indicated that soluble L1-CAM released from ovarian cancer
cells is a potent pro-angiogenic factor (Friedli et al., 2009).
Therefore in vivo experiments in animal models have to be
performed to determine the role of soluble L1-CAM in the
progression of melanoma. In tissue section of melanoma
patients, we did not find any correlation of ADAM10 and L1-
CAM expression. Nevertheless, we observed a clear correla-
tion between L1-CAM and ADAM10 expression in our cell
line array from melanoma patients. Importantly, overexpres-
sion of L1-CAM and ADAM10 has been observed in a
subpopulation of colorectal cancer cells at the invasive front
of tumors (Gavert et al., 2005). It can be noted that, the
expression of both proteins confers metastatic capacity of
colorectal cancer cells to the liver (Gavert et al., 2005).
Another interesting finding of our study is the nuclear
ADAM10 expression in tissue sections of melanoma patients.
Importantly, nuclear ADAM10 was more often observed in
melanoma metastasis. Recently, it has been reported that the
nuclear translocation of ADAM10 contributes to the patho-
genesis and progression of human prostate cancer (Arima
et al., 2007). It has been shown, that ADAM10 can be
processed by ADAM-9, ADAM-15, and the g-secretase
(Tousseyn et al., 2009) The resulting intracellular ADAM10
domain translocates to the nucleus, where it may regulate
gene transcription (Tousseyn et al., 2009). Although we could
not detect ADAM10 protein in nuclei of MeWo cells, further
experiments should be performed to characterize the role of
nuclear ADAM10 expression in the progression of melanoma.
In summary, our data provide evidence that ADAM10 and
L1-CAM have important roles in the progression of malignant
melanoma. Additional in vivo experiments have to be
performed to confirm the important roles of ADAM10 and
L1-CAM in the progression of malignant melanoma to clarify
the potential of these molecules as new attractive targets in
the treatment of this aggressive and lethal skin disease.
MATERIALS AND METHODS
Skin samples, TMAs, and cell line array
Three different TMAs representing 46 primary melanomas and 127
melanoma metastasis were used for immunohistochemical analysis.
All melanomas had a Breslow tumor thickness of X1.0mm. Of the
46 patients, 23 had a Breslow tumor thickness from 1 to 2mm,
whereas tumor thickness was over 2mm in 23 patients. The
metastases array included 21 lymph nodes and 106 organ metastases.
Furthermore, we analyzed a cell line array of 50 melanoma patients.
The cell lines were derived from 21 primary cutaneous melanomas
and 24 metastasis, and 5 cell lines were of unknown origin.
Metastasis and melanoma cell lines were not related to the initially
described malignant melanomas. Cell lines were grown and cell line
array and TMAs were constructed as previously described (Mihic-
Probst et al., 2007). Furthermore, in order to avoid sampling error,
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immunohistochemistry was also carried out on 25 whole embedded
melanomas (15 primary tumors and 10 metastasis). In addition, we
investigated 17 whole embedded nevi.
Approval for the use of the reported melanoma TMAs,
melanomas, and nevi were obtained from the ethical commission
in Zurich. In addition, patients provided written informed consent on
the use of their tissue samples for the establishment of melanoma cell
cultures. The study was conducted according to the Declaration of
Helsinki Principles.
Immunohistochemistry
Paraffin tissue sections were deparaffinized in xylene, rehydrated
through a graded ethanol series, and washed in 10mM phosphate-
buffered 150mM saline, pH 7.4. Antigen retrieval technique was
performed by incubating the tissue sections for 20minutes in 0.01M
sodium citrate buffer, pH 6.0, in a microwave oven (500W). Tissue
sections were treated with 3% H2O2 in methanol for 30minutes at
room temperature. After blocking with phosphate-buffered saline (PBS)
containing 10% horse serum and 1% BSA for 1hour, the sections were
incubated with an Avidin/Biotin Blocking Kit (Linaris, Wertheim,
Germany) following the manufacturer’s protocol. The serial sections
were incubated overnight at 4 1C with a polyclonal rabbit ADAM10 Ab
(Chemicon, Hampshire, UK). After washing the slides, the Universal
Quick Kit (Linaris) was used to stain the skin sections. As a substrate, the
AEC Substrate Kit purchased from BioGenex (San Ramon, CA) was used
to detect the immune complexes. The slides were incubated with
hematoxylin (Roth, Karlsruhe, Germany) to counterstain the sections.
The sections were inspected with a Zeiss microscope (Go¨ttingen,
Germany) coupled to a 12-bit digital image camera. Immuno-
histochemical stainings on TMAs were carried out using an automated
immunostainer (Ventana Medical Systems, Tucson, AZ), using the
following Abs: anti-ADAM10 (dilution 1:100; Millipore, AB 19026),
anti-L1-14.10 (dilution 1:10; Professor P. Altevogt, Heidelberg,
Germany), and Mib-1 (dilution 1:20; Dako A/S, Hamburg, Germany).
Cell culture
The human keratinocyte cell line HaCaT and the melanoma cell
lines MeWo and Sk Mel 5 were provided by Professor Jo¨rg Reichrath
(Department of Dermatology, The Saarland University Hospital,
Homburg/Saar, Germany). The growth medium for all three cell lines
was RPMI supplemented with fetal bovine serum (10%), 2mM
L-glutamine, penicillin (100Uml1), and streptomycin (100mgml1).
Cloning of human ADAM10
Human umbilical vein endothelial cells were cultured in Endothelial Cell
Growth Medium (PromoCell GmbH, Heidelberg, Germany) supplemen-
ted with 5% fetal calf serum in humidified air with 5% CO2 at 37 1C.
After stimulation with 12-O-tetradecanoylphorbol-13-acetate (1mM) for
4hours, cells were harvested and total RNA was extracted using the
TRIzol reagent (Invitrogen, Carlsbad, CA). Poly(A) mRNA was isolated
from total RNA with NucleoTrap mRNA Kit (Macherey-Nagel, Du¨ren,
Germany) and then reverse transcribed with the Transcriptor High
Fidelity cDNA Synthesis Kit (Roche, Mannheim, Germany). Human
ADAM10 cDNA was amplified using a blend of equal units of GoTaq
polymerase (Promega GmbH, Mannheim, Germany) and Pfu DNA
polymerase (Fermentas, Vilnius, Lithuania), primer pair 50-TGCGGC
CGCAGGTGCTTCGCCGTTTCT-30 (forward) and 50-CTAAGCTTTTGG
CA-AGTGATGTCTCCAAT-30 (reverse) and 1mg cDNA as template.
Later, the amplicon was cloned in the expression vector pcDNA 3.1/
Zeo() (Invitrogen, Karlsruhe, Germany) using restriction enzymes NotI
and Hind III.
siRNA transfection
For downregulation of endogenous ADAM10 expression, the
following siRNA duplex (MWG Biotech AG, Ebersberg, Germany)
was used: 50-AGACAUUAUGAAGGAUUAUTT-30. For downregula-
tion of L1-CAM the following siRNA duplex (MWG Biotech AG) was
used: 50-AGGGAUGGUGUCCACUUCAAATT-30. As a negative
control, unspecific scrambled siRNA duplexes (50-AGGUAGU-
GUAAUCGCCUUGTT-30) were used.
At 24hours before transfection, 1 105 cells were seeded in six-
well plates. Transfection of siRNA was carried out using Oligofecta-
mine (Invitrogen, Karlsruhe, Germany) and 10nM siRNA duplex (MWG
Biotech AG) per well. Transfection was performed as previously
described (Elbashir et al., 2001). Specific silencing of targeted genes
was confirmed by at least two independent experiments.
Western blot
Cell extracts were prepared and processed as described recently
(Wiechen et al., 2001) at the indicated times. Western blot
membranes were incubated with a rabbit Ab against human
ADAM10 at a dilution of 1:2,000 (Calbiochem, Darmstadt,
Germany) in 2% nonfat dry milk dissolved in TTBS buffer (20mM
Tris, 150mM NaCl, pH 7.5, 0.1% Tween 20). Blots were developed
using the ECL system (Amersham Pharmacia, Buckinghamshire, UK).
To confirm equal loading, blots were re-probed with an b-actin Ab
(Sigma, Deisenhofen, Germany).
Nucleofection
Cells were nucleofected using materials supplied in the Amaxa Cell
Line Optimization Nucleofector Kit (Lonza, Cologne, Germany). A
total of 2 106 MeWo cells were suspended in Cell Line
Nucleofector Solution V (added with supplement) and mixed with
5mg ADAM10-pcDNA 3.1 plasmid DNA. Control cells were
transfected with empty pcDNA 3.1 plasmid DNA. The final volume
did not exceed 120ml. The solution was then pulsed with the T-20
Nucleofector Program (Amaxa, Cologne, Germany). Immediately
after pulsation, 500ml of pre-warmed Roswell Park Memorial
Institute (RPMI) 1640 medium (Sigma, St Louis, MO) was added to
each cuvette. The cells were transferred to a 1.5-ml Eppendorf tube
and incubated at 37 1C. After 10minutes, the nucleofected cells
were transferred to a six-well plate containing fresh, pre-warmed
RPMI medium (0.7 106cells per well) and maintained at 37 1C.
Nucleus isolation
Cells (1 107 cells) grown on a 10-cm dish were trypsinized and
washed twice with PBS and once with 10ml of buffer A (10mM Tris-
HCl pH 7.4, 8.3mM KCl, 1.3mM NaCl, 1.5mM MgSO4). After each
step, the cells were sedimented (10minutes, 660 g) and finally
resuspended in 10ml of buffer A. Later cells were swollen for
30minutes on ice, sedimented, and resuspended in 20ml of buffer B
(buffer A complemented with 0.5% NP-40 and 1mM phenylmetha-
nesulfonyl fluoride). Nuclei and cytosol were separated by passing
the suspension eight times through a 23-gauge needle followed by
20 times in a glass homogenizer. Nuclei were sedimented
(10minutes, 1,000 g), resuspended in 5ml of buffer C (buffer A
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complemented with 1mM phenylmethanesulfonyl fluoride) and
sedimented further (10minutes, 1,000 g). The purified nuclei were
resuspended in 300 ml of the lysis buffer.
FACS analysis
Keratinocytes and melanoma cells were incubated for 30minutes
with mAbs against ADAM10 (R&D Systems, Wiesbaden, Germany)
or L1 11A (Professor P. Altevogt, Heidelberg, Germany). After
washing the cells twice with PBS, a FITC-conjugated goat anti-
mouse Ab (Dako, Hamburg, Germany) was added to the cells and
incubated in the dark for 20minutes. After washing the cells twice
with PBS, stained cells were analyzed using a FACS cell analyzer
(Becton Dickinson, Heidelberg, Germany) using CellQuest Software
(Becton Dickinson).
Fluorescence microscopy
Cells were grown on coverslips and fixed with 4% paraformalde-
hyde/PBS. After washing the cells with PBS, cells were permeabi-
lized and blocked with 0.1% Triton X-100/PBS containing 5% BSA.
The anti-human ADAM10 ectodomain Ab (1:200 dilution) or L1 11A
Ab (1:500 dilution) was incubated for 1 hour at room temperature.
After washing thrice, bound Abs were detected by Alexa Flour 488-
conjugated goat anti-rabbit or Cy3-conjugated goat anti-mouse
(Molecular Probes, Karlsruhe, Germany) secondary Abs. After PBS
washing, nuclei were stained with 4,06-diamidino-2-phenylindole
(Sigma, Munich, Germany) and the cells were mounted in
Fluoromount-G (Biozol, Eching, Germany) and examined by
fluorescence microscopy (Keyence, Neu-Isenburg, Germany) or
using an LSM 510 Meta confocal laser-scanning microscope (Carl
Zeiss, Jena, Germany).
Proliferation assay
At 24 hours after the transfection of siRNAs, the MeWo cells or SK
Mel 5 cells were seeded into 96-well plates. For evaluation of the
anchorage-independent cell growth, plates were coated with poly-2-
hydroxyethyl methacrylate (Sigma, Deisenhofen, Germany). Cell
growth was monitored after 24, 48, and 72 hours using a CellTiter 96
Non-Radioactive Cell Proliferation Assay (Promega GmbH). The
formation of formazan through cleavage of the MTT tetrazolium salt
assay in metabolically active cells was measured at the absorbance
of 570 nm using a spectrophotometer. Each assay was performed in
triplicates and repeated at least thrice. Data are presented by
means±SD. Statistical and significant differences were determined
using Student’s t-test.
Cell-cycle analysis
Cells were seeded in six-well plates and transfected with siRNA as
described before. At 48 hours after siRNA transfection, cells were left
untreated or treated with 40 mM cisplatin (CDDP) for 24 hours. Cells
were trypsinized, washed in PBS, and incubated overnight at 4 1C in
500ml pure ethanol. After centrifugation for 10minutes, cells were
incubated in 300ml hypotonic solution containing 50 mgml1
propidium iodide, 0.1% sodium citrate, 0.1% Triton X-100, and
20 mgml1 DNase-free RNase A for 30minutes at 37 1C. Finally,
cells were analyzed using flow cytometry in linear mode. Each assay
was performed in triplicates and repeated at least thrice. Data are
presented by means±SD. Statistical and significant differences were
determined using Student’s t-test.
Cell adhesion assay
Plates (24-well) were coated for 1 hour with 10 mg fibronectin, 6.4 or
64 mgml1 soluble L1-CAM. The production of soluble human L1-
CAM has been described elsewhere (Oleszewski et al., 1999).
MeWo cells were detached from culture vessels and 1 105 cells
were incubated in 100ml medium for 2 hours under normal culture
conditions. After washing the plate and fixing the remaining cells
with 4% paraformaldehyde, cells were stained with crystal violet
solution. The eluted dye was measured at 595 nm in an ELISA reader.
Cell migration assay
The effect of ADAM10 and L1-CAM knockdown on melanoma cell
migration was measured as the ability of cells to migrate through
Transwell filters (6.5mm diameter, 5mm pore size). Transwell filters
were coated with fibronectin (10 mgml1 in PBS) or Matrigel for
1.5 hours before adding the cells. At 24 hours after the siRNA
transfection, cells were detached by trypsinization and 1 105 cells
were seeded into Transwell filters in the 100ml starvation medium.
500ml Growth medium was placed in the lower compartment, and
the cells were left to migrate for 18–24 hours. To test the effect of
soluble L1-CAM on cell migration, 10 ngml1, 1mgml1, or
10 mgml1 soluble L1-CAM was added to the cells, before they
were seeded into the Transwell filters. Nonmigrated cells were
removed by a cotton swab, the transmigrated cells at the backside of
the filter were stained with crystal violet solution as described
(Mechtersheimer et al., 2001). The eluted dye was measured at
595 nm in an ELISA reader. Each experiment was performed in
triplicates and repeated at least thrice. Data are presented by
means±SD. Statistical and significant differences were determined
using Student’s t-test.
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